Skip to main content
. 2019 Jul 1;9:9482. doi: 10.1038/s41598-019-45890-w

Figure 2.

Figure 2

Combined PC945 and posaconazole treatment within an in vitro model of the human alveolus. (A) Time course comparison of compounds alone or combined against azole-susceptible A. fumigatus (NCPF2010) penetration of the bilayer, vehicle infection control (●), PC945 (0.1 μg/mL, upper, ■), posaconazole (0.01 μg/ml, lower, Δ), combination (○). n = 3 (BE) Representative images of histological analysis of A. fumigatus (NCPF2010) infected bilayer, with mono- or combined compound administration, [haematoxylin & eosin staining (x400)], (B) A. fumigatus infection control, (C) posaconazole (0.01 μg/ml, lower), (D) PC945 (0.1 μg/ml, upper) and (E) combined. Arrows: fugal body, (F) Time course comparison of compounds alone or in combination against azole-resistant A. fumigatus (TR34/L98H) penetration of the bilayer, vehicle infection control (●), PC945 (1 μg/mL, upper, ■), posaconazole (0.1 μg/ml, lower, Δ), combined (○). n = 3 *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.